Anzupgo 20 mg

Delgocitinib, the active ingredient in ANZUPGO, is a JAK inhibitor presented as a 20 mg/g cream for topical use. It is used to treat moderate to severe chronic hand eczema in adults who have not responded adequately to topical corticosteroids or for whom they are not advisable. GNH USA supplies ANZUPGO as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

ANZUPGO is a prescription medication specifically designed for the treatment of chronic hand eczema. It works by modulating the immune system to reduce inflammation and alleviate symptoms associated with this condition.

ANZUPGO is a topical medication used to treat moderate to severe chronic hand eczema in adults. It is particularly beneficial for those who have not responded to other treatments or for whom topical corticosteroids are not suitable.

- Chronic hand eczema: Reduces inflammation and alleviates symptoms such as redness, itching, and irritation in the hands and wrists. - Moderate to severe cases: Effective for cases that are not well-controlled with other treatments. - Topical application: Specifically designed for use on the skin of the hands and wrists.

ANZUPGO may cause various side effects, ranging from common to serious. It is important to be aware of these potential reactions when using the medication.

Common Side Effects: - Application site reactions: Pain, tingling, itching, or redness in the area where the medicine was applied. - Skin and nail infections: Increased risk of bacterial or fungal infections in the treated area. - Low white blood cell counts: May affect the body's ability to fight infections.

Serious or Rare Side Effects: - Serious infections: Increased risk of infections such as tuberculosis, herpes zoster, and other systemic infections. - Non-melanoma skin cancer: Potential increased risk of certain types of skin cancer. - Allergic reactions: Severe allergic reactions, although rare, can occur.

When using ANZUPGO, it is important to follow certain precautions to ensure safe and effective treatment. Always consult with a healthcare provider before starting this medication.

- Inform your doctor: Tell your healthcare provider about all medical conditions, especially if you have an infection or are scheduled to receive a vaccine. - Avoid live vaccines: Do not receive live vaccines before, during, or after treatment with ANZUPGO. - Pregnancy and breastfeeding: It is not known if ANZUPGO will harm an unborn baby or pass into breast milk. Consult your healthcare provider for guidance. - Avoid other JAK inhibitors: Do not use ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants. - Active infections: Do not start using ANZUPGO if you have an active, serious infection unless directed by your healthcare provider. - Store at room temperature: Keep the medication away from moisture and heat. Do not freeze.

ANZUPGO may interact with other medications, which can affect its effectiveness or increase the risk of side effects. It is important to be aware of these potential interactions.

Major Interactions (Avoid): - Other JAK inhibitors: Avoid using ANZUPGO in combination with other JAK inhibitors to prevent increased risk of side effects. - Potent immunosuppressants: Do not use ANZUPGO with other potent immunosuppressants to avoid compromising the immune system.

Moderate Interactions (Monitor Closely): - Vaccines: Consult your healthcare provider before receiving any vaccines while using ANZUPGO. - Other topical medications: Inform your healthcare provider about all topical medications you are using to avoid potential interactions. - Medications affecting the immune system: Monitor closely when using ANZUPGO with other medications that affect the immune system.